History Says September Is a Terrible Month for the S&P 500 Index and for Other Stocks. Here's Why I'm Still Investing Anyway.

September has historically been the weakest month for major U.S. equity benchmarks: the Dow and S&P 500 have each averaged a 1.1% decline, while the Nasdaq has averaged a 0.9% loss. The article argues against selling solely because of seasonal weakness, citing Vanguard and BlackRock evidence that missing the market's best days can materially impair long-term returns; BlackRock says S&P 500 investments grew more than eightfold over the past two decades, but missing the 10 best days would have reduced returns by more than half. Investors considering sales should also account for capital-gains taxes and wash-sale constraints.

Analysis

This is not a fundamental information event and should not alter directional equity exposure. Calendar seasonality is a weak standalone signal: the historical average drawdown is small relative to normal monthly volatility, while the article offers no evidence on current positioning, dealer gamma, earnings revisions, or macro conditions—the variables that determine whether seasonal weakness becomes a tradable correction.

The more relevant near-term mechanism is behavioral: widely publicized September caution can modestly increase retail de-risking and demand for index hedges, lifting VIX and skew before any realized selloff. That can create a better entry point for systematically adding quality beta, but only if the weakness is not accompanied by deteriorating credit spreads, declining earnings breadth, or a rates shock. BLK marginally benefits from continued retail participation and AUM-market beta, whereas NVDA and NFLX should trade primarily on AI capex/earnings and subscriber-ad economics rather than the calendar.

Contrarian view: consensus awareness of the ‘September Effect’ reduces its usefulness. If implied volatility rises without a corresponding move in high-yield spreads or downward EPS revisions, the more attractive trade is likely to sell expensive index downside protection or buy equity exposure into weakness. Over 6-18 months, valuation and profit delivery—not month-of-year effects—remain the relevant drivers of multiple direction.

Key Decisions for Investors

• No outright portfolio de-risking based solely on seasonality; maintain fundamental positions in NVDA, NFLX, and BLK. Treat any broad 3-5% SPX decline over the next 1-3 months as a potential staged-buying opportunity only after confirming stable high-yield spreads and unchanged forward EPS estimates.
• Set a tactical alert: if VIX moves above 25 while HY OAS remains below 400 bp and SPX forward 12-month EPS is not revised down, consider selling 1-2 month SPX put spreads or adding SPY exposure in tranches. The thesis is falsified by HY OAS widening above 450 bp or a material earnings-revision downturn.
• For existing concentrated long equity books, use defined-risk hedges rather than cash liquidation: buy 1-3 month SPY put spreads financed partially with lower-strike puts, sized to protect a 5-8% drawdown. Avoid naked volatility shorts given event-risk from rates and macro data.
• Do not infer a trade in NFLX or NVDA from this item. Reassess only around company-specific catalysts—NVDA supply-chain commentary and hyperscaler capex revisions; NFLX advertising-tier monetization and subscriber/ARPU guidance—where a broad risk-off move could create idiosyncratic entry levels.